41789-95-1

Basic information

• Product Name: 3-METHOXY-N-METHYLBENZYLAMINE 97
• Synonyms: 3-METHOXY-N-METHYLBENZYLAMINE 97;N-(3-METHOXYBENZYL)-N-METHYLAMINE;(3-methoxybenzyl)methylamine;1-(3-methoxyphenyl)-N-methylmethanamine;3-Methoxy-N-methylbenzylamine;3-METHOXY-N-METHYLBE;(3-methoxybenzyl)methylamine(SALTDATA: FREE);[(3-Methoxyphenyl)Methyl](Methyl)aMine
• CAS NO: 41789-95-1
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.21
• Product Categories: Amines;C9 to C10;Nitrogen Compounds
• Mol File: 41789-95-1.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 130-133 °C28 mm Hg(lit.)
• Flash Point: 212 °F
• Appearance: /
• Density: 1.014 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.106mmHg at 25°C
• Refractive Index: n20/D 1.5290(lit.)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Soluble in chloroform, dichloromethane, ethyl acetate and methan
• PKA: 9.65±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-METHOXY-N-METHYLBENZYLAMINE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXY-N-METHYLBENZYLAMINE 97(41789-95-1)
• EPA Substance Registry System: 3-METHOXY-N-METHYLBENZYLAMINE 97(41789-95-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41-43
• Safety Statements: 26-36/37/39
• WGK Germany: 2
• HazardClass: IRRITANT
• Hazardous Substances Data: 41789-95-1(Hazardous Substances Data)

Usage

Description

3-METHOXY-N-METHYLBENZYLAMINE 97, also known as 3-Methoxy-N-Methylbenzylamine, is an organic compound that serves as an intermediate in the synthesis of various pharmaceuticals. It is a liquid with specific chemical properties that make it a valuable component in the production of certain medications.

Uses

Used in Pharmaceutical Industry:
3-METHOXY-N-METHYLBENZYLAMINE 97 is used as an intermediate in the synthesis of diclofensine hydrochloride for its role in the development of pain-relieving and anti-inflammatory medications. Its chemical properties contribute to the effectiveness and potency of the final product, making it a crucial component in the pharmaceutical industry.

InChI:InChI=1/C9H13NO/c1-10-7-8-4-3-5-9(6-8)11-2/h3-6,10H,7H2,1-2H3/p+1

Upstream product

• 593-51-1 methylamine hydrochloride 
• 591-31-1 3-methoxy-benzaldehyde 
• 959922-04-4 N-(3-methoxyphenylmethyl)carbamic acid ethyl ester 
• 17101-98-3 (4-methyl-benzyl)carbamic acid ethyl ester 
• 1711-05-3 m-anisoyl chloride 
• 874-98-6 1-bromomethyl-3-methoxybenzene 
• 16928-30-6 N-(3-methoxybenzylidene)methanamine 
• 74-89-5 methylamine 

Downstream Products

• 148235-03-4 (3-methoxy-benzyl)-(4-methoxy-benzyl)-methyl-amine 
• 143426-11-3 N-(3-methoxybenzyl)-N-methyl-2,2-diethoxyethylamine 
• 1254941-88-2 1-(3,4-dichlorophenyl)-2-((3-methoxybenzyl)(methyl)amino)ethanone 
• 1262999-60-9 2-((3-methoxybenzyl)(methyl)amino)benzaldehyde 
• 1273874-92-2 5-bromo-N-(3-methoxybenzyl)-N-methylthiophene-2-carboxamide 
• 1183462-00-1 3-bromo-N-(3-methoxybenzyl)-N-methylbenzamide 
• 1285248-71-6 5-bromo-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide 
• 1350734-93-8 3'-methoxy-N-(3-methoxybenzyl)-N-methyl[1,1'-biphenyl]-4-carboxamide 
• 1350734-94-9 3'-hydroxy-N-(3-hydroxybenzyl)-N-methyl[1,1'-biphenyl]-4-carboxamide 
• 1350734-95-0 N-(3-methoxybenzyl)-n,3'-dimethyl[1,1'-biphenyl]-4-carboxamide 
• 1350734-96-1 N-(3-hydroxybenzyl)-n,3'-dimethyl[1,1'-biphenyl]-4-carboxamide 
• 1350734-97-2 4'-methoxy-N-(3-methoxybenzyl)-N-methyl[1,1'-biphenyl]-3-carboxamide 
• 1350734-98-3 4'-hydroxy-N-(3-hydroxybenzyl)-N-methyl[1,1'-biphenyl]-3-carboxamide 
• 1350734-99-4 3'-methoxy-N-(3-methoxybenzyl)-N-methyl[1,1'-biphenyl]-3-carboxamide 

Relevant articles and documents

Enabling Synthesis of Triple Reuptake Inhibitor (+)-BMS-820836, a Potential Therapeutic Agent for the Treatment of Depression

Herein, we describe the enabling synthesis of (+)-BMS-820836, a 4,7-disubstituted tetrahydroisoquinoline which was developed as a treatment for a range of neurological diseases, including depression and neurophatic pain. In order to advance the drug candi

CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE

The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.

Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors

RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (～7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.